Updates and interpretations of the NCCN Clinical Practice Guide 2ed version 2023 on pancreatic adenocarcinoma
BAI Rui
SUN Bei
Abstract：Pancreatic ductal adenocarcinoma has poor biological behavior and poor prognosis.How to standardize its diagnosis and treatment to further improve postoperative survival rate and long-term quality of life is a challenge faced by pancreatic surgeons.The National Comprehensive Cancer Network(NCCN)guidelines released the second edition of pancreatic cancer diagnosis and treatment guidelines this year on June 19,2023.Compared with the previous version,the new version of the guidelines has made the following updates:the NALIRIFOX protocol has officially entered the first-line treatment of locally advanced and metastatic pancreatic cancer;the functional status score is divided into good(0-1),intermediate(2),and poor(3-4);some new drugs have been included in the scope of targeted treatment for pancreatic cancer,the overall treatment tends to be precise,comprehensive and effective.The NCCN guidelines wield authoritative influence globally and the anticipation for further evidence-based medicine to emerge in the future is expected to standardize the treatment of pancreatic cancer.
Keywords：pancreatic ductal adenocarcinomanational comprehensive cancer network(NCCN)precision medicine
Publication Date：2024-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 85-88 )